Inhibition of PI3K and MEK: It is all about combinations and biomarkers

Brent N. Rexer; Ritwik Ghosh; Carlos L. Arteaga

doi:10.1158/1078-0432.CCR-09-0872

Inhibition of PI3K and MEK: It is all about combinations and biomarkers

Brent N. Rexer, Ritwik Ghosh, Carlos L. Arteaga

Research output: Contribution to journal › Comment/debate › peer-review

35 Scopus citations

Abstract

A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.

Original language	English (US)
Pages (from-to)	4518-4520
Number of pages	3
Journal	Clinical Cancer Research
Volume	15
Issue number	14
DOIs	https://doi.org/10.1158/1078-0432.CCR-09-0872
State	Published - Jul 15 2009

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-09-0872

Cite this

@article{ebc55a98f3594f7c9da799c85b8176eb,

title = "Inhibition of PI3K and MEK: It is all about combinations and biomarkers",

abstract = "A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.",

author = "Rexer, {Brent N.} and Ritwik Ghosh and Arteaga, {Carlos L.}",

year = "2009",

month = jul,

day = "15",

doi = "10.1158/1078-0432.CCR-09-0872",

language = "English (US)",

volume = "15",

pages = "4518--4520",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "14",

}

TY - JOUR

T1 - Inhibition of PI3K and MEK

T2 - It is all about combinations and biomarkers

AU - Rexer, Brent N.

AU - Ghosh, Ritwik

AU - Arteaga, Carlos L.

PY - 2009/7/15

Y1 - 2009/7/15

N2 - A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.

AB - A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.

UR - http://www.scopus.com/inward/record.url?scp=68049102319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049102319&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-0872

DO - 10.1158/1078-0432.CCR-09-0872

M3 - Comment/debate

C2 - 19584146

AN - SCOPUS:68049102319

SN - 1078-0432

VL - 15

SP - 4518

EP - 4520

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 14

ER -

Inhibition of PI3K and MEK: It is all about combinations and biomarkers

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this